Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy

Locally Advanced Pancreatic Adenocarcinoma Clinical Trial

— LAPSTAR  

Official title:

Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy, a Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06272162
• Other study ID #: NL85622.041.24
• Secondary ID: 1503023U-0725
• Status: Not yet recruiting
• Phase: N/A
• Start date: February 2024
• Est. completion date: January 2030

Study information

• Verified date: February 2024
• Source: UMC Utrecht
• Contact: Lois Daamen, MD, PhD
• Phone: + 316 51223276
• Email: L.a.daamen-3[@]umcutrecht.nl
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized controlled trial comparing the effect of local ablative MR-guided radiotherapy (MRgRT) after systemic therapy with current standard treatment alone, on health-related quality of life in patients with locally advanced pancreatic cancer (LAPC).

Description:

Rationale: About 40% of patients with pancreatic cancer are diagnosed with locally advanced pancreatic cancer (LAPC). Recommended treatment consists of chemotherapy to prevent disease dissemination and prolong survival. Nevertheless, local tumor growth often causes severe morbidity, including pain, gastrointestinal obstruction, and malnutrition. This has a substantial negative impact on health-related quality of life (HRQoL). Eventually, one-third of patients die due to local tumor growth rather than from systemic disease spread. For palliation of symptoms and improved local tumor control, potentially prolonging survival, minimally-invasive ablative therapies may be effective. Online adaptive stereotactic Magnetic Resonance-guided radiotherapy (MRgRT) is an innovative treatment modality that enables high-precision ablative radiotherapy for pancreatic tumors. This potentially improves RT efficacy without increasing the risk of RT-related toxicity. Consequently, MRgRT holds promise for the treatment of pancreatic cancer.

Objective: To investigate the efficacy of stereotactic MRgRT on HRQoL deterioration-free survival, including death as an event, in patients with LAPC after systemic chemotherapy.

Study design: Nationwide randomized controlled trial (1:1 randomization).

Study population: Patients with LAPC according to Dutch Pancreatic Cancer Group (DPCG) criteria who are not eligible for tumor resection after at least two months of chemotherapy (sample size 150 patients). Also, patients with LAPC who are eligible but choose to refrain from chemotherapy and/or surgery can participate in this trial.

Intervention: Patients in the intervention arm receive 50Gy MRgRT in five fractions over two weeks in one of the four Consortium Centers, followed by standard care, either consisting of continuation of chemotherapy or best supportive care. Patients in the control arm continue standard care without ablative MRgRT.

Main study endpoints: The primary outcome is HRQoL deterioration-free survival from the time of randomization, defined as the Time Until Definitive Deterioration (TUDD) including death as an event. HRQoL is evaluated using the EORTC QLQ-C30 Summary Score. The TUDD is defined as a 10-point minimal clinically important difference compared to baseline, with no further improvement of ≥10 points afterwards. All patients will be offered home monitoring using the Trial@home platform to decrease the burden of trial participation.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 150
• Est. completion date: January 2030
• Est. primary completion date: January 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Pathology proven pancreatic ductal adenocarcinoma (PDAC);

• At least two (preferably four) months systemic therapy with (m)FOLFIRINOX and/or gemcitabine + nab-paclitaxel; or eligibility for chemotherapy but no initiation of chemotherapy based on patients' wish;

• No option for surgical resection, either because anatomical irresectability based on the surgeon's judgement (assessed on imaging or during explorative laparotomy) and/or frailty (unfit for surgery or chemotherapy) and/or no surgery based on patient's wish.

• No evidence of distant metastatic disease progression, evaluated by CT Thorax / Abdomen / Pelvis and/or PET-CT scan;

• Performance status WHO 0-2.

Exclusion Criteria:

• Contra-indications for MRI or CT with an intravenous contrast agent according to the protocol of the local radiology and/or radiotherapy departments

• Contraindications for MRgRT, as determined by the involved expert radiation oncologists of the Consortium

• <18 years old

• Pregnancy

Related Conditions & MeSH terms

• Locally Advanced Pancreatic Adenocarcinoma

Intervention

Radiation:
• MR guided radiotherapy
5 fractions of 10 Gray MRgRT in addition to standard of care

Locations

Country	Name	City	State
Netherlands	Amsterdam University Medical Center, VUmc	Amsterdam	Noord-Holland
Netherlands	Catharina Hospital	Eindhoven	Noord- Brabant
Netherlands	Radboud University Medical Center	Nijmegen
Netherlands	University Medical Center Utrecht	Utrecht

Sponsors (6)

Lead Sponsor	Collaborator
UMC Utrecht	Amsterdam UMC, location VUmc, Catharina Ziekenhuis Eindhoven, Centre for Human Drug Research, Netherlands, Dutch Pancreatic Cancer Group (DPCG), Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HRQoL deterioration-free survival	HRQoL deterioration-free survival is defined as the Time Until Definitive Deterioration (TUDD) including death from any cause, calculated from the time of randomization. HRQoL is primarily assessed using the EORTC QLQ-C30 (version 3.0) Summary Score.	Through study completion, an average of 18 months
Secondary	Overall survival	The time interval between LAPC diagnosis and either death from any cause or last follow-up	From the date of LAPC diagnosis untill either death from any cause or last follow-up, whichever came first, assessed up to 18 months
Secondary	Patient reported Quality of Life EORTC QLQ-PAN26	Part of the Patient Reported Outcome Measures (PROMs) using EORTC QLQ-PAN26	At baseline and at 2,4, weeks and subsequently every 2 months. Assessed through study completion, up to 18 months
Secondary	Patient reported Quality of Life EORTC QLQ-C30	Part of the Patient Reported Outcome Measures (PROMs) using EORTC QLQ-C30	At baseline and at 2,4, weeks and subsequently every 2 months. Assessed through study completion, up to 18 months
Secondary	Patient reported Quality of Life EQ5D-5L	Part of the Patient Reported Outcome Measures (PROMs) using EQ5D-5L	At baseline and at 2,4, weeks and subsequently every 2 months. Assessed through study completion, up to 18 months
Secondary	The need of subsequent treatments	To assess continuation of systemic therapy and/or administration of subsequent treatments (e.g., surgery, second-line systemic treatment, experimental treatment in clinical studies etc.), recommendations from multidisciplinary team meetings, reasons for refraining from recommended therapy, and reasons for discontinuation of therapy (i.e., start of best supportive care)	Through study completion, an average of 18 months
Secondary	Treatment response assessed on CT-imaging (graded according to RECIST guidelines)	To assess tumor response on imaging according to RECIST criteria in patients who received imaging procedures during follow-up (no part of the trial follow-up)	with available imaging during 18 months follow-up
Secondary	CA 19.9 response	To assess serum CA 19-9 response in patients in whom serum CA 19-9 is measured (no part of the trial follow-up)	Through study completion, an average of 18 months
Secondary	Trial@home monitoring related outcome: feasibility Withings Steel HR smartwatch	To assess the feasibility of the Trial@home monitoring via the Withings Steel HR smartwatch for home monitoring of pancreatic cancer patients.; Compliance Withings Steel HR smartwatch (wear-time): amount of time (hours) in a day that the participant wears the smartwatch. This is calculated by the amount of time the device registers a heart rate. Patients wearing the device for >50% of the observation period will be considered as feasible.	Through study completion, an average of 18 months
Secondary	Trial@home monitoring related outcome: feasibility Body+ scale	To assess the feasibility of the Trial@home monitoring via the Body+ scale for home monitoring of pancreatic cancer patients.; Compliance rates Body+ scale: compliance with weekly weight measurements is calculated by the number of completed weight measurements divided by the total amount of weeks in the observation period. A compliance rate of at least 75% will be considered as feasible.	Through study completion, an average of 18 months
Secondary	Trial@home monitoring related outcome: feasibility Whitings Sleep	To assess the feasibility of the Trial@home monitoring via the Whitings Sleep for home monitoring of pancreatic cancer patients.; Compliance Whitings Sleep: compliance with daily sleep monitoring is calculated by the number of nights sleep is measured. A compliance rate of at least 75% nights per week will be considered as feasible.	Through study completion, an average of 18 months
Secondary	Trial@home monitoring related outcome: feasibility ePRO application	To assess the feasibility of the Trial@home monitoring via the ePRO application for home monitoring of pancreatic cancer patients.; Compliance questionnaires through the ePROapplication: A compliance rate of at least 75% from the scheduled assessments will be considered as feasible.	Through study completion, an average of 18 months
Secondary	Trial@home monitoring related outcome: digital biomarkers	To exploratively generate digital biomarkers and quantify the correlation between data obtained from the Trial@home platform (Withings Steel HR smartwatch, a Withings Body+ Scale, a Withings Sleep, ePRO) and clinical endpoints (e.g., unplanned hospitalizations, early signs of adverse events, clinical deterioration, performance status, quality of life)	Through study completion, an average of 18 months
Secondary	Intervention arm related outcome toxicity	To assess acute (3 months) RT-related toxicity measured from the start of MRgRT, according to CTCAE v527	Through study completion, an average of 18 months
Secondary	Intervention arm related outcome, completion of therapy	To assess completion of therapy	Through study completion, an average of 18 months
Secondary	Intervention arm related outcome diffusion weighted images	To assess correlation of diffusion weighted images at each treatment fraction and the possible correlation with outcomes for patients treated on a 1.5T MR-Linac	Through study completion, an average of 18 months